NOVOGEN ANNOUNCES THE OUTCOME OF A COMPREHENSIVE SCIENCE REVIEW Novogen will focus the development programs for each of our three lead candidates to achieve the earliest possible initiation of clinical studies. We affirm our goal to have two products enter clinical development in 2016 Specific indications, formulations and routes of administration have been confirmed for each program with emphasis on achieving robust data-driven milestones required to meet pre-clinical and clinical regulatory requirement The Company’s extensive medicinal chemistry expertise and compound library coupled with its ongoing collaborations with Yale University and the University of NSW enables us to further strengthen, protect and target our future discovery programs and our intellectual property estate Further management and staff appointments have been made to strengthen inhouse capabilities in terms of manufacturing, project management, intellectual property and investor relations expertise High quality candidates have been identified for the permanent CEO position including some from overseas. Interviewing of final short-listed candidates will commence mid-October with view to announcing an appointment by year-end. Recruitment of a CMO (Chief Medical Officer) is ongoing The Company is in a strong financial position to support the progression of the lead programs through to the clinic
NRT Price at posting:
15.0¢ Sentiment: Hold Disclosure: Held
